Systemic therapy for advanced pancreatic neuroendocrine tumors

Seminars in Oncology

Volumn 40, Issue 1, 2013, Pages 75-83

  Kulke, Matthew H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CHLOROZOTOCIN; DACARBAZINE; DOXORUBICIN; EDOTREOTIDE; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; OCTREOTIDE; OXALIPLATIN; PASIREOTIDE; PAZOPANIB; PLACEBO; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE;

ADVANCED CANCER; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; DRUG SAFETY; FATIGUE; HUMAN; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC THERAPY; THYROID DISEASE; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; INDOLES; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PYRROLES; SIROLIMUS; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84873388004     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.11.010     Document Type: Article

References (68)

1. J. Strosberg, N. Gardner, L. Kvols Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas Pancreas 38 2009 255 258
2. A.I. Vinik, M.R. Gonzales New and emerging syndromes due to neuroendocrine tumors Endocrinol Metab Clin North Am 40 2011 19 63
3. S. Song, R. Shi, B. Li Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors Pancreas 38 2009 811 814
4. C.B. Lambers, T. Lind, S. Moberg Omeprazole in Zollinger-Ellison syndrome Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists N Engl J Med 310 1984 758 761
5. H. Shojamanesh, F. Gibril, A. Louie Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma Cancer 94 2002 331 343
6. G.M. Portela-Gomes, M. Stridsberg, L. Grimelius Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4 Endocr Pathol 18 2007 79 85
7. M.L. Healy, S.J. Dawson, R.M. Murray Severe hypoglycaemia after long-Acting octreotide in a patient with an unrecognized malignant insulinoma Intern Med J 37 2007 406 409
8. A. Rinke, H.H. Muller, C. Schade-Brittinger Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group J Clin Oncol 27 2009 4656 4663
9. W.W. de Herder, L.J. Hofland, A.J. van der Lely Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours Endocr Relat Cancer 10 2003 451 458
10. H.A. Schmid Pasireotide (SOM230): development, mechanism of action and potential applications Mol Cell Endocrinol 286 2008 69 74
11. L. Kvols, B. Wiedenmann, K. Oberg et al. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR: results of a phase II study J Clin Oncol 2006 ASCO Annual Meeting
12. E. Wolin, L. Kvols, S. Ezzat Pasireotide LAR in patients with metastatic carcinoid tumors: pharmacokinetics (PK) and safety results from a randomized, multicenter, phase I study 2009 Gastrointestinal Cancers Symposium 2009 [abstract 93]
13. J.A. Chan, D.P. Ryan, A.X. Zhu Phase I study of pasireotide (SOM230) in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2010
14. D.J. Kwekkeboom, W.W. de Herder, E.P. Krenning Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors Endocrinol Metab Clin North Am 40 2011 173 185
15. D.J. Kwekkeboom, W.W. de Herder, B.L. Kam Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 26 2008 2124 2130
16. 3]octreotate J Nucl Med 52 2011 1361 1368
17. 90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 29:2416-23.
18. L. Villard, A. Romer, N. Marincek Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers J Clin Oncol 30 2012 1100 1106
19. 90Y-edotreotide for metastatic carcinoid refractory to octreotide J Clin Oncol 28 2010 1652 1659
20. K. Oberg, K. Funa, G. Alm Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome N Engl J Med 309 1983 129 133
21. K. Oberg, B. Eriksson The role of interferons in the management of carcinoid tumors Acta Oncol 30 1991 519 522
22. M. Di Bartolomeo, E. Bajetta, N. Zilembo Treatment of carcinoid syndrome with recombinant interferon alpha-2a Acta Oncol 32 1993 235 238
23. S. Faiss, U.F. Pape, M. Bohmig et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group J Clin Oncol 21 2003 2689 2696
24. R. Arnold, A. Rinke, K.J. Klose Octreotide versus octreotide plus interferon-Alpha in endocrine gastroenteropancreatic tumors: a randomized trial Clin Gastroenterol Hepatol 3 2005 761 771
25. M. Valimaki, H. Jarvinen, P. Salmela Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 67 1991 547 549
26. C.G. Moertel, M. Lefkopoulo, S. Lipsitz Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma N Engl J Med 326 1992 519 523
27. P. Cheng, L. Saltz Failure to confirm major objective antitumor activity ofr streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma Cancer 86 1999 944 948
28. A.D. McCollum, M.H. Kulke, D.P. Ryan Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors Am J Clin Oncol 27 2004 485 488
29. M.A. Kouvaraki, J.A. Ajani, P. Hoff Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas J Clin Oncol 22 2004 4762 4771
30. R.K. Ramanathan, A. Cnaan, R.G. Hahn Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma Study of the Eastern Cooperative Oncology Group-E6282 Ann Oncol 12 2001 1139 1143
31. E. Bajetta, L. Ferrari, G. Procopio Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumors Ann Oncol 13 2002 614 621
32. M.F. Stevens, J.A. Hickman, S.P. Langdon Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5- tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine Cancer Res 47 1987 5846 5852
33. S. Ekeblad, A. Sundin, E.T. Janson Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors Clin Cancer Res 13 2007 2986 2991
34. F. Maire, P. Hammel, S. Faivre Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors Neuroendocrinology 90 2009 67 72
35. M. Kulke, J. Hornick, C. Frauenhoffer O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors Clin Cancer Res 15 2009 338 345
36. J.R. Strosberg, R.L. Fine, J. Choi First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas Cancer 117 2011 268 275
37. M.H. Kulke, K. Stuart, P.C. Enzinger Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors J Clin Oncol 24 2006 401 406
38. A.B. Schwarzberg, E.H. Stover, T. Sengupta Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide Cancer Invest 25 2007 249 255
39. M. Kulke, K. Stuart, C. Earle A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors J Clin Oncol ASCO Annual Meeting Proc 24 2006 4044
40. M. Kulke, L. Blaszkowsky Phase I/II study of everolimus (RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET) M AZ Gastrointestinal Cancers Symposium ASCO 2010 [abstract 223]
41. S.L. Gerson Clinical relevance of MGMT in the treatment of cancer J Clin Oncol 20 2002 2388 2399
42. M.R. Middleton, J.M. Lunn, C. Morris O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma Br J Cancer 78 1998 1199 1202
43. O.L. Chinot, M. Barrie, S. Fuentes Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide J Clin Oncol 25 2007 1470 1475
44. A.A. Brandes, A. Tosoni, G. Cavallo Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study J Clin Oncol 24 2006 4746 4753
45. M.E. Hegi, A.C. Diserens, T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
46. H.S. Friedman, R.E. McLendon, T. Kerby DNA mismatch repair and O6-Alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma J Clin Oncol 16 1998 3851 3857
47. E. Bajetta, L. Catena, G. Procopio Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59 2007 637 642
48. P. Kunz, T. Kuo, J. Zahn A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors ASCO Annual Meeting 2010 [abstract 4104]
49. E. Bergsland, A. Ko, M. Tempero A Phase II trial of Folfox plus bevacizumab in advanced, progressive neuroendocrine tumors ASCO Gastrointestinal Cancer Symposium 2008 [abstract 216]
50. J. Zhang, Z. Jia, Q. Li Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors Cancer 109 2007 1478 1486
51. M. Inoue, J.H. Hager, N. Ferrara VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis Cancer Cell 1 2002 193 202
52. M.H. Kulke, H.J. Lenz, N.J. Meropol Activity of sunitinib in patients with advanced neuroendocrine tumors J Clin Oncol 26 2008 3403 3410
53. E. Raymond, L. Dahan, J.L. Raoul Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 2011 501 513
54. A. Vinik, E.V. Cutsem, P. Niccoli Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET) J Clin Oncol ASCO Annual Meeting 30 suppl 2012 [abstract 4118]
55. T.J. Hobday, J. Rubin, K. Holen MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): a Phase II Consortium (P2C) study J Clin Oncol ASCO Annual Meeting Proc 25 2007 [abstract 4505]
56. A. Phan, J. Yao, D. Fogelman A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC) a J Clin Oncol ASCO Annual Meeting Proc 2010 [abstract 4044]
57. J. Capdevilla, R. Salazar, I. Halperin Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors Cancer Metastasis Rev Suppl 1 2011 27 34
58. R. Zoncu, A. Efeyan, D. Sabatini mTOR: from growth signal integration to cancer, diabetes and aging Nat Rev Mol Cell Biol 12 2011 21 35
59. E. Missiaglia, I. Dalai, S. Barbi Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway J Clin Oncol 28 2010 245 255
60. Y. Jiao, C. Shi, B. Edil DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors Science 331 2011 1199 1203
61. J.C. Yao, A.T. Phan, D.Z. Chang Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study J Clin Oncol 26 2008 4311 4318
62. J. Yao, C. Lombard-Bohas, E. Baudin Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial J Clin Oncol 28 2010 69 76
63. J.C. Yao, M.H. Shah, T. Ito Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
64. M.H. Kulke, E.K. Bergsland, J.C. Yao Glycemic control in patients with insulinoma treated with everolimus N Engl J Med 360 2009 195 197
65. J. Yao, A. Phan, D. Fogleman Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker J Clin Oncol 2010 [abstract 4002]
66. E. Bajetta, L. Ferrari, G. Procopio Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours Ann Oncol 13 2002 614 621
67. M. Kulke, L. Blaszkowsky, A. Zhu Phase I/II study of everolimus (RAD001) in combination with temozolomide (TMZ) in patients (pts) with advanced pancreatic neuroendocrine tumors (NET) 2010 Gastrointestinal Cancers Symposium 2010 [abstract 127]
68. I. Duran, J. Kortmansky, D. Singh A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas Br J Cancer 95 2006 1148 1154